New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b );  ; influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275);  ; influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 );   - solution for injection - 0.5 ml - active: influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b )   influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275)   influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 )   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin potassium chloride sodium chloride water for injection - vaxigrip is indicated for the prevention of influenza caused by influenza virus types a and b in adults and children aged 6 months and over.

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - influenza vaccine, split virion, inactivated - suspension for injection in pre-filled syringe - influenza vaccine (split virion, inactivated) a/victoria/4897/2022 (h1n1) pdm09 - like strain (a/victoria/4897/2022 ivr-238 15 µg a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227 15 µg b/austria/1359417/2021 - like strain (b/austria/1359417/2021 bvr-26 15 µg b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type) - vaccines

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - influenza vaccine, split virion, inactivated - suspension for injection - influenza vaccine (split virion, inactivated) 15 µg - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; water for injections; potassium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:,- active immunisation of adults, including pregnant women, and children from 6 months of age and older,- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women (see sections 4.2 dose and method of administration, 4.4 special warnings and precautions for use, 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; water for injections; potassium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:,- active immunisation of adults, including pregnant women, and children from 6 months of age and older,- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women (see sections 4.2 dose and method of administration, 4.4 special warnings and precautions for use, 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties ? clinical trials).

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection

Israel - English - Ministry of Health

sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:- active immunisation of adults, including pregnant women, and children from 6 months of age and older- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women.the use of vaxigrip tetra should be based on official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: dl-alpha-tocopheryl acid succinate; potassium chloride; sodium chloride; water for injections; polysorbate 80; dibasic sodium phosphate dodecahydrate; magnesium chloride hexahydrate; octoxinol 10; monobasic potassium phosphate - fluarix tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types a and b contained in the vaccine (see section 5.1 pharmacodynamic properties, clinical trials).,the use of fluarix tetra should be based on official recommendations.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (sanofi - influenza virus split virion - suspension for injection

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - injection - see ingredients - each 0,5 ml suspension contains influenza virus vaccine a influenza virus vaccine a